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Abstract
Despite of multitude investigations no reliable prognostic immunohistochemical biomark-
ers in GIST have been established so far with added value to predict the recurrence risk of
high risk GIST besides mitotic count, primary location and size. In this study, we analyzed
the prognostic relevance of eight cell cycle and apoptosis modulators and of TP53 muta-
tions for prognosis in GIST with high risk of recurrence prior to adjuvant treatment with
imatinib. In total, 400 patients with high risk for GIST recurrence were randomly assigned
for adjuvant imatinib either for one or for three years following laparotomy. 320 primary
tumor samples with available tumor tissue were immunohistochemically analyzed prior to
treatment for the expression of cell cycle regulators and apoptosis modulators cyclin D1,
p21, p16, CDK4, E2F1, MDM2, p53 and p-RB1. TP53 mutational analysis was possible in
245 cases. A high expression of CDK4 was observed in 32.8% of all cases and was asso-
ciated with a favorable recurrence free survival (RFS), whereas high expression of MDM2
(12.2%) or p53 (35.3%) was associated with a shorter RFS. These results were indepen-
dent from the primary KIT or PDGFRA mutation. In GISTs with higher mitotic counts was a
significantly increased expression of cyclin D1, p53 and E2F1. The expression of p16 and
E2F1 significantly correlated to a non-gastric localization. Furthermore, we observed a sig-
nificant higher expression of p21 and E2F1 in KIT mutant GISTs compared to PDGFRA
mutant and wt GISTs. The overall frequency of TP53 mutations was low (n = 8; 3.5%) and
could not be predicted by the immunohistochemical expression of p53. In summary, muta-
tion analysis in TP53 plays a minor role in the subgroup of high-risk GIST before adjuvant
treatment with imatinib. Strong expression of MDM2 and p53 correlated with a shorter
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Introduction
95% of gastrointestinal stromal tumors (GIST) exhibit an overexpression of the receptor tyro-
sine kinase KIT [1]. Approximately 90% harbor a mutation in the KIT gene or in the gene of
the homolog receptor tyrosine kinase PDGFRA. These mutations lead to ligand independent,
constitutive activation of the kinases and play a central role in GIST development [2]. A
minority of GIST without gain-of-function mutations in one of these two kinases display other
genetic and epigenetic changes [3–5]. These alterations are located in the BRAF (rapidly accel-
erated fibrosarcoma B) gene, in the succinate dehydrogenase (SDH) complex or the insulin-like
growth factor 1 receptor (IGF1R) gene [6]. Furthermore, Hur et al. showed that especially genes
of the cell cycle control are altered in high risk compared to low risk GIST [7]. One such gene
is TP53 encoding a 64 kDa protein (p53). Its gene product p53 is an essential regulator of
many genes controlling apoptosis, senescence, DNA damage repair and cell cycle arrest [1].
Upon radiation-induced damage, p53 is activated as an element of the G1-phase checkpoint to
allow DNA repair. Activation of p53 leads to the induction of p21 (CDKN2A) that binds to
and inactivates cyclin-dependent kinases (CDK) complexed with cyclins’ (cyclin = CCN:
cyclin D1/CDK4, cyclin D1/CDK6 and cyclin E1/CDK2). Consequently, the cell cycle is
arrested [8]. Without this p21-induced inhibition complexed CDKs and cyclins phosphorylate
the retinoblastoma 1 (RB1) protein that dissociates from E2F1 transcription factor. As a result
transcriptional activation of a series of target genes leads to the progression of the cell cycle.
The frequency of TP53 alterations is heterogeneous among different tumor entities. Less
than 5% of cervical carcinoma harbor a TP53 mutation whereas in ovarian carcinoma the
TP53 gene is altered in up to 90% [9]. Most of the mutations result in non-functional proteins
destroying the normal tumor suppressing functions of p53 (TP53). Consequently, mutations
in this gene are associated with accelerated tumor formation, higher stage, poor prognosis and
low response to therapy [10–13]. A targeted therapy against mutated TP53 is under develop-
ment and some inhibitors are currently investigated in clinical trials [14–16]. Alternatively,
loss-of-function mutations of TP53 can be inactivated by other regulators of the cell cycle that
convey p53 downstream effects as shown for MDM2 (mouse double minute 2) [11] and for
CDK4 (cyclin dependent kinase 4) [17]. MDM2 binds either to the p53 transactivation domain
to interfere with p53 transcriptional regulatory mechanism or promotes p53 proteasomal deg-
radation by its ubiquitin ligase activity [18]. So the mechanisms how the tumor suppressor
function of p53 is disturbed are diverse and the expression level of different cell cycle regula-
tors in GIST may allow a deeper understanding of the p53 activation or inactivation status
besides inactivating by TP53 mutations. Targeted therapy against mutated p53 is under devel-
opment and some inhibitors are currently investigated in clinical trials [14–16].
Another potentially relevant mechanism of GIST progression towards a more aggressive
biological behaviour is a partial deletion of chromosome 9 playing an essential role in the
transformation from a low to a high risk GIST [19, 20]. One possible result of this deletion is a
p16 (CDKN2A) loss which normally functions as an inhibitor of the cell cycle. Inactivating
mutations in this gene or its deletion seem to be essential to increase cell cycle activity and con-
sequently to progress from low to high risk GIST.
Cell cycle regulators in GIST
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In this study, we examined the TP53 mutation frequency as well as the expression of clini-
cally relevant cell cycle regulators and apoptosis modulators that are associated with impaired
p53 function in 320 high risk GIST prior to adjuvant imatinib treatment cyclin D1 (CCND1),
CDK4, p21 (CDKN1A), p16 (CDKN2A), E2F1, MDM2, p-RB1 and p53.
Materials and methods
Patient samples
Between February 2004 and September 2008, 400 patients with a high-risk GIST were included
to the randomized, multicenter Scandinavian Sarcoma Group (SSG) trial XVIII, carried out
in collaboration with the SSG and the German Working Group of Medical Oncology [Arbeits-
gemeinschaft Internistische Onkologie (AIO)]. The study, a protocol-based pre-specified
analysis, was approved by the Operative Ethics Committee of the Helsinki University Central
Hospital (identifier NCT00116935).
Furthermore, ethical approvals were given from all local ethical committees of the other
participating centers in Finland, Sweden, Norway and Germany. Before entering the study, the
participants signed a consent form and gave their agreement to the study. All data were de-
identified. In the study, patients who were diagnosed with gastrointestinal stromal tumor
(GIST) were randomly allocated in a 1:1 ratio to receive imatinib (Gleevec) either for 12 or for
36 months following surgery. The participants of the study had to have a histologically verified
GIST with a high risk of GIST recurrence despite complete removal of all macroscopic GIST
tissue at surgery.
A high risk for GIST recurrence was defined by the presence of at least one of the following
features: 1) the longest tumor diameter >10.0 cm, 2) tumor mitotic count>10 per 50 high
power fields of the microscope, 3) tumor diameter > 5.0 cm and mitotic count >5, or 4)
tumor rupture before surgery or at surgery. Two senior pathologists (E. W. and M. S.-R.)
reviewed the histological diagnoses and carried out mitotic counting as described in a previous
study [21]. Tissue from 320 primary GISTs, confirmed centrally to be GISTs, was available for
the current study. Immunohistochemistry for CD34, KIT, PDGFRA, DOG1 and KI67 was car-
ried out as described earlier [22, 23].
Mutation analyses were performed in 245 cases using Sanger sequencing for KIT exons 8, 9,
11, 13, 14, 15, 17 and PDGFRA exons 12, 14 and 18. Risk classification was done according to
the modified National Cancer Institute (NIH) scheme [24].
Immunohistochemistry
Immunohistochemical staining of cyclin D1 (also known as CCND1), CDK4, p21 (also known
as CDKN1A), p16 (also known as CDKN2A), E2F1, MDM2, p-RB1 and p53 (TP53) was per-
formed on an automatic stainer (medac GmbH, Wedel, Germany) using tissue microarrays
(TMA) containing formalin-fixed paraffin-embedded tumor cores in duplicates. In brief, 3 μm
sections were mounted on positively charged, adhesive slides and dried at 37˚C overnight. For
standard heat-induced epitope retrieval sections were boiled in citrate buffer pH 6 in case of
CDK4, p21 (CDKN1A), E2F1, p-RB1 and p53 (TP53) or in EDTA buffer pH 6 in case of cyclin
D1 (CCDN1), p16 (CDKN2A), MDM2 in a microwave oven. Primary antibody incubation
was performed for 30 min at room temperature with appropriate antibodies (S1 Table).
The sections were subsequently incubated with polymer Poly-HRP-GAM/R/RIgG for 15
min followed by incubation for 8 min with 3.3’-diaminobenzidine (DAB) and washed. Slides
were counterstained with hematoxylin.
Immunohistochemical score was adapted from Romeo et al. [25] and defined as follows:
staining in 0–10% of tumor cells: score 0; 11–20%: score 1; 21–30%: score 2; 31–40%: score 3;
Cell cycle regulators in GIST
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41–50%: score 4; 51–60%: score 5, 61–70%: score 6, 71–80%: score 7, 81–90%: score 8 and 91–
100%: score 9. The intensity score was divided up in no visible staining: score 0, weak staining:
score 1, moderate staining: score 2 and strong staining: score 3. Mean value of the sum and
intensity score was built up as an overall score for the final analysis A mean score of>0 was
regarded as high expression for cyclin D1 (CCND1), MDM2, CDK4 and p-RB1, one of>2 for
p16 (CDKN2A), p53 (TP53) and E2F1 and one of>3 for p21 (CDKN1A).
DNA isolation
In our cohort of 320 samples, 245 cases could be used for complete DNA isolation and
sequencing analysis of TP53 (76.6%). 75 samples had to be excluded from the analysis due to
poor DNA quality, low DNA amount or limited tissue availability. All samples were fixed in
neutral-buffered formalin prior to paraffin embedding (FFPE-samples). Tumor areas were
selected by a senior pathologist (E.W.) on a hematoxylin-eosin stained slide and DNA was
extracted from six corresponding unstained 10 μm thick slides by manual macro-dissection.
The DNA isolation was performed automatically using the BioRobot M48 (Qiagen, Hilden,
GER) as described before [26].
Sanger sequencing
Exon 4–8 of the TP53 gene (transcript ID: ENST00000269305, Ensemble Genome Browser,
Oct. 2012, http://www.ensembl.org/index.html, [27]) were amplified by PCR using specific
primers. TP53 exon 4 was divided into two PCR reactions due to the exon size (4a and 4b).
Primer sequences are listed in S2 Table.
5 μl of PCR products were purified with exonuclease I and Fast-AP (Thermo Fisher Scien-
tific, Waltham, USA) for 15 min at 37˚C and 15 min by 80˚C. A sequencing reaction was set
up with 1 or 2 μl of purified PCR products depending on the amount of PCR products and the
BigDye1 Terminator v1.1 Cycle Sequencing Kit (Thermo Fisher Scientific Inc.) following the
manufacturer’s instructions. The BigDyeXTerminator1 Purification Kit (Thermo Fisher Sci-
entific Inc.) was used for the purification of the DNA sequencing reactions removing non-
incorporated BigDye1 terminators and salts. The solution was incubated for 30 min with agi-
tation of 1800 rpm. The sequencing analyses were carried out on the 3500 Genetic Analyzer
(Thermo Fisher Scientific Inc.). The electropherograms were analyzed by visual inspection
and Sanger sequencing was repeated by an uncertain or mutated result.
Statistical analysis
The results of the immunohistochemical and mutation analyses were merged with the clinical-
pathological data. The data from the population to be evaluated was analyzed from February 4,
2004, through December 31, 2013, using SPSS statistical software, version 22.0 (SPSS Inc) as
described before [28]. The recurrence-free survival (RFS) was calculated using the Kaplan-
Meier method from the date of randomization to the date of GIST recurrence or death, censor-
ing patients alive and without recurrence on the date of the last follow-up. We compared the
survival rate between groups using a multivariate survival Cox proportional hazards model.
Results
Correlation of the expression of eight proteins with recurrence free survival
in primary GIST
Expression of p16 (CDKN2A), cyclin D1 (CCND1), p53 (TP53), p21 (CDKN1A), E2F1,
CDK4, MDM2 and p-RB1 expression are depicted in Table 1 and S3 Table.
Cell cycle regulators in GIST
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Among the samples of 157 females (49.1%) and 163 males (50.9%) with a median age of 61
years (range 23–83) we could detect a significant increase of p53 (TP53) expression with age
(p = 0.015, Mann-Whitney test). With increasing tumor size (median primary tumor size 9.4
cm; range 1.5–35.0) we observed a loss of cyclin D1 (CCND1, p = 0.040) and p21 (CDKN1A,
p = 0.037, Mann-Whitney test). No further significant association of cell cycle regulating pro-
tein expression was found with gender, tumor site and mutational status.
Concerning the mitotic count, a median of 6 mitoses per 50 HPF could be detected (range
0–135). GISTs with higher mitotic counts showed a significant increased expression of cyclin
D1 (CCND1), p53 (TP53) and E2F1 (p = 0.001, <0.001 and<0.001, respectively) whereas ele-
vated levels of p21 (CDKN1A), p16 (CDKN2A) and p-RB1 were found, these factors did not
reach significance. 167 (52.2%) of the tumors were localized in the gastric wall whereas 151
(47.5%) were localized elsewhere. The expression of p16 (CDKN2A) and E2F1 significantly
correlated to a non-gastric localization (p =<0.001 and p = 0.008 respectively, chi square test).
A significantly higher expression of p21 (CDKN1A, p = 0.009) and E2F1 (p = 0.022) could be
detected in KIT mutated GISTs compared to PDGFRAmutated and wt GISTs whereas no sig-
nificance was reached for the other proteins.
Concerning the RFS, GIST with high p53 (TP53) expression showed a significant lower five
years RFS (45.9%) than those with a low p53 expression (62.4%, p = 0.012, logrank test, Figs 1
and 2).
Similar results were obtained for the expression of E2F1. 243 samples were negative for the
expression of E2F1 whereas 77 were strongly positive correlating with a shorter RFS (45.3%
versus 60.7%; p = 0.027, log-rank test). Surprisingly, the expression of CDK4, observed in 105
cases, was associated with a longer RFS (p = 0.014, log-rank test, Figs 1 and 2).
No significant correlation of RFS and the expression of cyclin D1 (CCND1, p = 0.170), p21
(CDKN1A, p = 0.505), p16 (CDKN2A, p = 0.320), MDM2 (p = 0.060) and pRB1 (p = 0.605)
could be observed. In summary, it can be stated that although the high expression of p53
Table 1. Association of expression of 8 proteins in primary GIST with recurrence-free survival in the SSGXVIII trial.
Factor Cut-off (median) No. of tumours (%) 5-year RFS (%) p#
p16 (CDKN2A), mean 2 vs. 178 (55.6) 60.4
>2 142 (44.4) 52.2 0.320
Cyclin D1 (CCDN1), mean 0 vs. 178 (55.6) 55.0
>0 142 (44.4) 59.3 0.170
p53 (TP53), mean 2 vs. 207 (64.7) 62.4
>2 113 (35.3) 45.9 0.012
MDM2, mean 0 vs. 281 (87.8) 58.7
>0 39 (12.2) 46.7 0.060
CDK4, mean 0 vs. 215 (67.2) 52.2
>0 105 (32.8) 67.6 0.014+
p-RB1, mean 0 vs. 241 (75.3) 56.5
>0 79 (24.7) 57.8 0.605
p21 (CDKN1A), mean 3 vs. 185 (57.8) 59.0
>3 135 (42.2) 53.5 0.605
E2F1, mean 2 vs. 167 (52.2) 60.0
>2 153 (57.8) 53.2 0.234
# determined by log-rank test, p < 0.05 was defined as significance,
 Expression of TP53 is associated with an unfavorable recurrence-free survival,
+ CDK4 expression was associated with a better recurrence-free survival
https://doi.org/10.1371/journal.pone.0193048.t001
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Fig 1. Representative immunohistochemical stainings of CDK4, MDM2,p53, p21 and p16 expression. The
expression of different proteins was evaluated by immunohistochemistry. In (A), (C), (E), (G) and (I) the
representative high expression pattern of CDK4, MDM2 and p53 (TP53) in different GISTs are shown in contrast to
the non/low expression patterns (B), (D), (F), (H) and (J) (100x).
https://doi.org/10.1371/journal.pone.0193048.g001
Cell cycle regulators in GIST
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Fig 2. Recurrence free survival of patients with CDK4, MDM2 and p53 expression or TP53mutated tumors.
Kaplan-Meier survival curve showing analysis of recurrence free survival in patients from the SSGXVIII study. A high
expression of CDK4 is positively correlated with recurrence free survival (red line, p = 0.01) in contrast to a high
expression of MDM2 and p53 (TP53, red line, p = 0.06 and p = 0.01, respectively, log-rank test). TP53 mutations tend
to correlate to a worse recurrence free survival but did not reach significant levels due to a small number of mutated
tumors (p = 0.24, log-rank test).
https://doi.org/10.1371/journal.pone.0193048.g002
Cell cycle regulators in GIST
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(TP53) and E2F1 was significantly associated with a shorter RFS and the expression of CDK4
with a favorable RFS, in the multivariate survival analysis no independent prognostic value for
any of the cell cycle regulators could be determined. The result remained the same when the
duration of adjuvant imatinib (either for 1 year or for 3 years) was added as a covariable to the
model. The main immunohistochemical findings of this study are displayed in Table 2 and a
model of cell cycle regulators and apoptosis modulators in Fig 3.
TP53mutation frequency in GISTs
Nine of the 245 analyzed GIST samples exhibited a mutation in the TP53 gene (3.5%, Table 3,
Fig 4). No double mutations could be detected and only one case showed the TP53 mutation
in a low allelic frequency (case 9). Six of these mutations resulted in a non-functional protein,
two in a partially functional protein and one had no influence on the protein function [29]. A
closer look at the clinical-pathological findings reveals that eight of the nine TP53 mutated
GIST were suitable for mutation analysis of KIT and PDGFRA. Four cases harbored a KIT
exon 11, one sample a KIT exon 13, one case a PDGFRAmutation and one showed a wildtype
status for the two genes. Seven of the 167 gastric samples (52.2% of the whole cohort) showed a
TP53 mutation (4.2%). The other two TP53 mutations were detected in a GIST localized in the
colon and another in a small intestinal GIST.
Although no significant correlation was observed to tumor size, morphological subtype,
risk classification, localization and KIT/PDGFRAmutation, it is interesting to note that seven
of the nine TP53 mutated GIST were localized in the stomach including the one case with a
TP53 mutation not altering the protein function. Although gastric GISTs are thought to behave
less aggressive than intestinal GISTs they were overrepresented among the TP53 mutant
GISTs. Therefore we conclude that TP53 mutations tend to occur more frequently in gastric
GISTs associated with a worse RFS.
Discussion
In this study, we demonstrated that a high expression of CDK4 was surprisingly associated
with a favorable recurrence free survival (RFS), whereas a high expression of MDM2 or p53
(TP53) was associated with unfavorable RFS. These results were independent from the under-
lying primary KIT or PDGFRAmutation.
High p53 (TP53) expression is related to an increased half-life time of the mutated protein
[30, 31] Here, we showed that 7.1% (n = 2) of the 28 tumors with a high p53 (TP53) expression
showed a mutation in the TP53 gene. The screening of the whole cohort for TP53 mutations
revealed an overall frequency of 3.5%. This is in concordance with other studies showing a
very low TP53 mutation frequency despite a high TP53 protein expression in a higher number
Table 2. Main immunohistochemical findings of this study.
Protein Cases with high expression [%] Correlation with clinico-pathological parameters predicitve value
cyclin D1 (CCDN1) 44.4 tumor site, mitotic count -
p21 (CDKN1A) 42.2 KIT mutation -
p16 (CDKN2A) 44.4 tumor site -
CDK4 32.8 - Better RFS
E2F1 47.8 mitotic count, tumor site, KIT mutation -
MDM2 12.2 - Worse RFS
p53 (TP53) 35.3 age, mitotic count Worse RFS
p-RB1 24.7 - -
https://doi.org/10.1371/journal.pone.0193048.t002
Cell cycle regulators in GIST
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of GIST [11, 32–35]. One explanation of this mutation independent activation of p53 (TP53)
might be amplification or posttranscriptional modifications such as phosphorylation, acetyla-
tion or sumoylation [36, 37].
By correlating the TP53 status with clinico-pathological parameters, we demonstrated that
TP53 mutations tend to correlate with a poor RFS. Nevertheless, the results did not reached
significance. Obviously, TP53 mutations are a rather late event in GIST progression as the per-
centage of TP53 mutated GISTs was higher in the study of Romeo et al. in a metastatic GIST
cohort and in a study of Ryu et al. in a series of 125 localized GIST with 22% TP53 mutated
tumors. Interestingly, both studies preselected the tumor samples for mutation analysis
depending on their immunohistochemical p53 (TP53) expression which is, according to our
results, not a sensitive biomarker for the TP53 genotype.
Others have shown that TP53 mutations are necessary for the malignant progression of
breast cancer from lower to higher grades [38] and that these mutations therefore significantly
correlate to a higher mitotic count and a higher risk group in GIST [34]. In ovarian cancer
TP53 mutations significantly correlate to resistance to platinum-based chemotherapy and
Fig 3. Model of cell cycle regulators and apoptosis modulators that are associated with impaired p53 (TP53) function in GIST. Constitutive
activated KIT or PDGFRA promotes proliferation and can be inhibited by imatinib. Impaired p53 function leads as well to a higher proliferation and
inhibits apoptosis by modulation of cell cycle regulators. The analyzed proteins are displayed as circles with a bold boarder. Filled green circles indicate
that this protein is associated with a favorable recurrence free survival in our study, filled red circles indicate that these regulators are associated with an
unfavorable recurrence free survival.
https://doi.org/10.1371/journal.pone.0193048.g003
Cell cycle regulators in GIST
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shortened survival [39]. The same tendency could be observed in supratentorial WHO Grade
II astrocytomas and oligoastrocytomas [40] where TP53 mutations were unfavorable predic-
tors of progression free survival. In our cohort the absolute number of TP53 mutations in
GIST is too low to draw final conclusions. However, determining the TP53 mutational status
may help to identify patients with a relatively high risk of recurrence prior to treatment and
therefore the TP53 status should be considered to select patients who will best benefit from an
adjuvant treatment.
Furthermore, we could detect a significant correlation of high expression of MDM2 with
poor RFS. This is in concordance with the current literature. High MDM2 expression is corre-
lated with poor progression free survival in ovarian clear cell carcinoma [41] and with poor
overall survival in urothelial neoplasms of the bladder [42]. In GIST a high mRNA expression
of MDM2 is described with an aggressive clinical behavior and an unfavorable prognosis ana-
lyzing 38 GIST samples of all risk classifications [43].
We also detected a high expression of CDK4 in 32.8% of the cases. High expression of
CDK4 is frequently seen in human cancer [44]. Dai et al., analyzing triple negative breast can-
cer, described a high expression of CDK4 correlating with poor overall survival and relapse
free survival [45]. In contrast, Peurala et al., found no correlation of CDK4 expression with
survival data in human breast cancer [44]. An upregulation of CDK4 is described in 85% of
myxoid and round cell liposarcoma [46]. Furthermore, a high level of CDK4 amplification is a
poor prognostic marker in well-differentiated and dedifferentiated liposarcoma [47]. In GIST,
Table 3. Clinical and histopathological findings of GIST with TP53 mutations.
Case
No.
Age/
Gender
Localization Size
(cm)
Morphological
subtype
KIT/PDGFRA mutation TP53 mutation
(effect on
protein#)
TP53 (p53)
expression
Follow up
1 60/F Stomach 5.5 Epitheloid PDGFRA exon 18: p.
I843_D846del
Exon 8: p.H297Y
(non-functional)
Non/low 36 Mo; NED 9.0 yrs
2 67/M Stomach 13.0 Spindle KIT exon 13: p.K642E Exon 8: p.
A276Lfs29
(non-functional)
high 12 Mo; rec. 1.4 yrs,
DOD§ 4 yrs
3 66/M Stomach 6.0 Epitheloid
leiomyomatous
Wildtype~ Exon 5: p.V172F
(non-functional)
high 12 Mo; rec. 0.6 yrs,
DOD§ 1 yrs
4 54/F Colon 5.0 Spindle KIT exon 11: p.
K550_Q556delinsM
Exon 7: p.L257V
(non-functional)
high 12 Mo; rec. 5.7 yrs
5 56/F Stomach 6.0 Mixed PDGFRA exon 18: p.D842V Exon 4b: p.S94A
(functional)
high 36 Mo; rec. 0.9 yrs
6 26/F Small
intestine
15.0 Spindle KIT exon 11: p.V559D Exon 7: p.C242Y
(non-functional)
Non/low 36 Mo; rec. 3.2 yrs
7 71/F Stomach 10.5 Spindle KIT exon 11: p.
K550_Q556del
Exon 5: p.Q165K
(partially
functional)
Non/low 36 MO; NED 5.9 yrs
8 61/M Stomach 3.0 Epitheloid KIT exon 11: p.L576P Exon 5: p.A161S
(partially
functional)
Non/low 12 Mo; rec. 2.0 yrs
9 55/M Stomach 11.0 Spindle NA Exon8: p.R273H
(non-functional)
high 36 Mo; NED 5.2 yrs
NA, not available.
# According to the International Agency for Research on Cancer (IARC) TP53 database [29].
§ DOD, death of disease
 NED, no evidence of disease
~ immunohistochemically no loss of expression of succinate dehydrogenase subunit B (SDHB) was detected
https://doi.org/10.1371/journal.pone.0193048.t003
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Fig 4. Representative electropherograms of TP53mutated GIST samples. TP53 mutations were detected by Sanger sequencing.
Representative electropherograms are shown for each TP53 mutated sample (A-I) in the same order as shown in Table 1. Six mutations
resulted in a non-functional p53 (A-D, F, I), two mutations resulted in a partially functional p53 (G-H) and one mutation could be
detected without influence on the p53 function (E).
https://doi.org/10.1371/journal.pone.0193048.g004
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Sabah et al. detected CDK4 expression in 100% of the samples but without an association
between CDKs and histological classification [48].
CDK4 is an important regulator of the cell cycle G1 phase progression and the G1 to S
phase transition. In detail, CDK4 phosphorylates RB1 protein, lead to the inactivation of
RB1 and the dissociation from E2F1 transcription factor [49]. RB1 is a tumor suppressor
that undergoes periodic phosphorylation when cells transverse the cell cycle [50]. RB1 is
dephosphorylated when cells exit the mitosis and phosphorylated in late G1 phase and
remains so throughout the progression through S phase to mitosis. This results in the activa-
tion of multiple genes encoding proteins that are required for DNA synthesis or to enter the
S phase.
Therefore, the activated, hypophosphorylated RB1 protein restricts proliferation [51]. By
phosphorylation and therefore inactivation of RB1, CDK4 is an essential regulator of prolifera-
tion. CDK4 is crucial for various oncogenic transformation processes suggesting that many
cancer cells may be addicted to high CDK4 activity [44]. However, we detected a significant
correlation of CDK4 expression with a favorable RFS. This is in contrast to the current litera-
ture and in contrast to the findings expected from the biological function of CDK4. One expla-
nation might be the unique cohort of well-characterized high risk GIST prior to treatment and
the high number of samples analyzed. To our knowledge, this is the only study analyzing more
than 200 high risk GIST prior to treatment for the expression of cell cycle regulators.
Furthermore, we observed a significantly higher expression of E2F1 in KIT mutated GISTs
compared to PDGFRAmutated and wt GISTs, in tumors with non-gastric location and with
higher mitotic counts. Similarly, expression of p16 (CDKN2A) was upregulated in KIT com-
pared to PDGFRAmutated and wt GISTs and associated with a non-gastric location. GISTs
with higher mitotic counts showed a significantly increased expression of cyclin D1 (CCND1)
and p53 (TP53). These results are in concordance with other studies [43, 52, 53]. A comparable
p53 (TP53) expression profile was described in 25–38% of GISTs by different groups [34, 54–
56]. In a study of Romero et al., 2009, which analyzed samples from patients with advanced
metastasized GIST and which tested 400 mg versus 800 mg imatinib daily [25], proved that
tumors had a higher expression of p16 (CDKN2A, 57%) and of p53 (TP53, 47%), whereas
expression of p21 (CDKN1A, 27%) and cyclin D1 (CCND1, 8%) was lower. Their expression
data of MDM2 (in 13%) and CDK4 (in 31%) were comparable to our findings. The higher fre-
quency of p53 (TP53) immunohistochemical positive samples in their cohort of metastatic
GISTs may reflect the more advanced stage of disease compared to our cohort of still localized
non-metastatic but high risk GISTs prior to adjuvant imatinib treatment. In another study,
Haller et al. showed that GISTs with a KIT exon 11 deletion exhibited a higher cyclin D1
(CCND1) expression that correlated with an accelerated proliferation and shorter disease
free survival in untreated primary GISTs and that high mRNA expression of CDK4, p16
(CDKN2A), RB1, MDM2, p53 (TP53) and E2F1 correlated with poor prognosis [43, 57]. Sur-
prisingly, we detected a marginal significance between the lack of CCND1 (cyclin D1) expres-
sion and larger tumors. This is likely due to the SSGXVIII trial inclusion criteria, since patients
with a large GIST (>10 cm in diameter) were considered high risk GISTs regardless of the
tumor mitotic count (according to the modified NIH risk stratification scheme). Therefore,
many large GISTs with a small mitotic count were included in the trial, which explains the
marginally significant association between absence of CCND1 expression and a small tumor
diameter.
In our study on formalin-fixed, paraffin-embedded tissue, p16 (CDKN2A) showed no sig-
nificant correlation with RFS. This discrepancy might be due to the use of different material.
However, we detected a correlation of p16 (CDKN2A) expression with non-gastric localiza-
tion. Extra-gastrointestinal stromal tumors (E-GIST) show aggressive clinico-pathological
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parameters as shown for hepatic E-GIST (high mitotic counts: >5/50 HPF, large tumor size:
>5 cm) resulting in a high risk classification [58, 59]. Therefore, we could indirectly show that
the expression of p16 (CDKN2A) correlated with a worse prognosis.
In summary, although none of the eight histological parameters was independently associ-
ated with recurrence-free survival (RFS) in a multivariable analysis with the standard prognos-
tic factors, we demonstrated an increased expression of several cell cycle regulating proteins in
GIST. The result remained the same when the duration of adjuvant imatinib (either for 1 year
or for 3 years) was added as a covariable to the model.
Our study suggests that the expression of MDM2, CDK4 and p53 (TP53) and the muta-
tional status of TP53 may be useful to identify patients with high risk localized GIST who carry
an increased recurrence risk and may benefit from a prolonged adjuvant treatment with imati-
nib although the TP53 mutation frequency is very low in treatment naïve, high risk GIST.
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